An international team of scientists, led by researchers from Imperial College London and the University of Exeter, have found that levels of resistance to fungal infection treatments are rising, BBC News reported on Friday.
The findings, which have been published in Science, reveal a huge global increase in resistance to antifungal drugs over the last 30-40 years and that fungal infections have some of the highest mortality rates of infectious diseases.
The researchers are calling for new treatments, saying they are urgently needed.
Due to their weakened immune systems, transplant patients, those in intensive care, and cancer patients are most at risk.
The researchers also discovered a rise of new multidrug-resistant fungi, such as Candida auris – responsible for increasing rates of invasive fungal infections in hospitals across the globe. It was found to be resistant to all antifungal drugs and "presents a threat to intensive-care units" as it can survive standard decontamination efforts.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy